Codon-Optimized GLA Gene Expression in Cardiac Tissue via rAAV Vector
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for Fabry disease, particularly targeting cardiac tissue, face challenges due to insufficient transduction of human cardiomyocytes and poor uptake of recombinant AGA enzyme, leading to unmet medical needs and high cardiovascular mortality.
Innovation Solution
Development of codon-optimized nucleic acid molecules encoding human galactosidase A (AGA) with enhanced expression levels, combined with a recombinant adeno-associated virus (rAAV) vector system, specifically targeting cardiac tissue using a modified capsid and transcription control sequences to achieve higher AGA protein expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type AAV1 vector is used for cardiac gene therapy, then liver targeting is achieved, but cardiac tissue transduction is insufficient
Solution Approach 1:
The patent modifies the AAV capsid protein at specific locations to confer cardiac tissue specificity. By introducing point mutations or peptide insertions at particular epitopes on the capsid surface, the vector achieves localized recognition by cardiac tissue receptors while maintaining overall viral structure and function.
Solution Approach 2:
The patent alters the physical-chemical parameters of the AAV capsid through amino acid substitutions. These changes in capsid composition modify the vector's tissue tropism, transforming it from liver-targeting (AAV1) to cardiac-targeting capability while preserving viral packaging and delivery functions.
2Reliability
If recombinant AGA enzyme is administered, then enzyme replacement therapy is provided, but cellular uptake is poor leading to insufficient treatment efficacy
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver the GLA gene directly into cardiac cells. Rather than administering recombinant enzyme that must be taken up by cells, the viral vector serves as a mediator that facilitates efficient gene delivery and sustained endogenous enzyme production within the target tissue.
Solution Approach 2:
The patent employs codon-optimized GLA gene sequences that are pre-adapted for high-level expression in human cells. This preliminary optimization of the transgene ensures that once delivered by the AAV vector, the gene produces maximum enzyme activity, compensating for any potential uptake limitations.
3Productivity
If codon-optimized GLA gene is delivered via AAV vector, then AGA protein expression is enhanced, but vector complexity increases
Solution Approach 1:
The patent divides the complex vector construction into separate modular components: the codon-optimized GLA cDNA insert, the AAV backbone elements (ITRs, promoter, polyA signal), and the capsid gene. This segmentation allows independent optimization of each module and simplifies the overall assembly process through standardized cloning techniques.
Solution Approach 2:
The patent uses codon optimization tables and algorithms that replicate successful coding sequences from highly expressed human genes. By copying proven codon usage patterns from constitutively expressed genes, the GLA transgene achieves high expression levels without requiring complex regulatory element design.
Data Source
AI summary
The present disclosure provides codon optimized nucleotide sequences encoding human alpha-galactosidase A, vectors, and host cells comprising codon optimized alpha-galactosidase A sequences, and methods of treating disorders such as Fabry disease comprising administering to the subject a codon optimized sequence encoding human alpha-galactosidase A.